BAFF/APRIL系统研究进展

BAFF和APRIL是新近发现的TNF配体超家族2个关系密切的成员。虽然它们共用2个受体BCMA和TACI,但转基因和基因敲除小鼠模型揭示它们各自功能并不冗余。BAFF是外周血B细胞一个关键的存活与成熟因子,它的活性通过其特异性受体BAFF-R调节,其过表达与自身免疫性疾病发生和B细胞肿瘤形成有关。APRIL在不依赖T细胞的Ⅱ型抗原反应和T细胞存活过程中扮演重要角色,同时它也能诱导一些非淋巴细胞的增殖和存活,在许多肿瘤细胞株和肿瘤组织文库中发现有高表达的APRIL。针对BAFF/APRIL系统设计出治疗相关疾病的生物制剂有着非常令人乐观的应用前景。     

BLyS受体TACI、BCMA与人IgG1 Fc融合蛋白在哺乳动物细胞中的表达与鉴定

从人肝脏和肾脏cDNA文库中扩增了人IgG1Fc与B淋巴细胞刺激因子 (BLyS)的受体TACI及BCMA的胞外编码区 ,构建了TACI Fc及BCMA Fc融合表达质粒pSec1 Fc TACI与 pSec1 Fc BCMA ,并使用电穿孔法转染COS 7细胞 ,从 1L无血清培养上清中可纯化得到分泌表达的TACI Fc与BCMA Fc融合蛋白约 2mg。为获得TACI Fc与BCMA Fc的稳定来源 ,构建了TACI Fc与BCMA Fc的CHO稳定表达细胞株。免疫沉淀和ELISA结果显示 ,TACI Fc及BCMA Fc能特异性地结合其配体BLyS而不与BLyS同家族的TNF结合。TACI Fc及BCMA Fc可阻断BLyS对体外培养的小鼠B淋巴细胞的促增殖作用     

可溶性VEGF受体Flt-1的基因克隆及其活性产物在原核中的表达

可溶性血管内皮细胞生长因子受体 ( Flt- 1 )具有受体拮抗剂作用 ,可竞争结合血管内皮细胞生长因子 ,( VEGF)并与其膜表面受体 Flt- 1及 KDR形成异源二聚体 ,最终阻断 VEGF的生物学活性 .利用 RT- PCR技术从人脐静脉内皮细胞扩增出 Flt- 1胞外 ～ 区 c DNA片段 ,通过基因重组将该片段克隆于谷胱甘肽转移酶 ( GST)融合蛋白表达载体 PGEX2 -T中 ,连接产物转化大肠杆菌XL1 - blue,经 IPTG诱导可获大量稳定表达的 Flt- 1 - GST融合蛋白 .该表达产物经变性复性处理后 ,可特异性结合 12 5 - VEGF.大量具有活性的可溶性 Flt- 1的获得有助于新的抗肿瘤血管形成方法的探索 .     

人可溶性APRIL(sAPRIL)基因的克隆及在大肠杆菌中的表达

从GenBank中查找出人APRIL蛋白 (编号:075888)序列 ,取其部分胞外 (sAPRIL)序列设计引物 ,用RT PCR从扁桃体总RNA中扩增出人sAPRIL基因 ,经克隆测序后进行同源比较 ,证实所克隆的基因即为sAPRIL。克隆载体经酶切后构建了表达载体 ,并在大肠杆菌中表达 ,纯化蛋白后进行细胞学实验表明sAPRIL有明显刺激肿瘤细胞增殖的作用 ,为深入研究sAPRIL的功能奠定了基础     

重组人ASCT2胞外结构域ECL2在大肠杆菌中的表达及其鉴定

中性氨基酸转运蛋白(ASCT2)是人类内源性病毒的包膜蛋白合胞素在细胞膜上的主要受体,ECL2是该受体的其中一个较大的胞外结构域.通过RT-PCR方法从人乳腺癌MCF-7细胞中克隆ASCT2基因编码区全长序列,再从中扩增ASCT2的胞外区ECL2序列,与pET-41b连接构建原核表达载体,重组质粒在大肠杆菌中获得高效表达,重组蛋白在N-和C-端分别融合谷胱甘肽转移酶(GST)和His6标签,融合蛋白在上清液和包涵体中均有表达,可溶性部分经亲和层析纯化获得高纯度的重组蛋白,该蛋白可结合在表达合胞素的MCF-7细胞表面,具有结合合胞素的潜在活性,这些结果为进一步研究ASCT2与合胞素的相互作用奠定了基础.     

小鼠核因子κB受体活化因子配基(RANKL)活性区cDNA在毕赤酵母中分泌型表达

由小鼠骨组织提取总RNA ,采用RT PCR扩增得到小鼠核因子κB受体活化因子配基(RANKL)活性区域cDNA .将该cDNA片段克隆入表达载体pPIC9,重组载体转化巴斯德毕赤酵母GS115细胞 ,筛选Mut+表型 ,经甲醇诱导实现目的基因的分泌型表达 .Tricine SDS PAGE显示 ,表达产物约 2 6kD ,经Western印迹鉴定 ,表达产物可被RANKL抗体识别 .采用硫酸铵盐析、CM SephadexC 2 5层析纯化重组蛋白 .经测定 ,发酵液上清重组蛋白表达量约 11mg L .采用破骨细胞样细胞(osteoclastlikecell,OLC)诱导分化实验检测重组蛋白的生物活性 ,证实该重组蛋白可以促进OLC的生成 ,并呈现剂量依赖关系     

HER-2/neu胞外配体结合区2在大肠杆菌中可溶性表达及纯化

用PCR技术扩增HER 2 neu胞外配体结合区 2 (RLD2 )cDNA ,并将扩增的基因片段克隆于硫氧还蛋白 (TrxA)原核表达载体中 ,获得TrxA RLD2融合蛋白的可溶性表达 .通过插入偶联翻译序列 ,实现TrxA与RLD2蛋白在大肠杆菌中的共表达 .表达产物经免疫印记检测可被抗HER 2 neu特异性抗体识别 .经离子交换层析和钴亲和层析纯化 ,RLD2蛋白的纯度达 90 % .用质谱法分析RLD2蛋白的分子量 ,与预期值相符 .结果表明 ,利用TrxA表达体系在大肠杆菌中获得了HER 2 neuRLD2蛋白高效可溶性表达     

人B淋巴细胞刺激因子C端肽的免疫增强作用

用套式PCR从人胎脑cDNA文库中克隆了B淋巴细胞刺激因子C端肽 (C terminalpeptideofBlymphocytestimulator,C BLyS)的cDNA。在大肠杆菌BL2 1CodonPlus (DE3)RIL中以包含体形式表达了C BLyS。对包含体的复性条件进行了摸索 ,建立了C BLyS的透析复性与纯化方法。经复性和纯化的C BLyS可结合其受体B细胞成熟抗原 (Bcellmaturationantigen ,BCMA) 人IgG1Fc融合蛋白 ,刺激体外培养的小鼠脾脏细胞增殖 ,并且可明显增强小鼠对溶菌酶的免疫应答水平。     

HLA-B2704重链胞外功能区基因片段的克隆表达及其生物学功能的初步鉴定

目的:克隆及可溶性表达 HLA-B*2704重链胞外功能区,并对其生物学功能进行初步鉴定.方法:以HLA-B 位点全长 cDNA 为模板,用 PCR-SSP 方法扩增 HLA-B*2704重链胞外区 cDNA,经测序鉴定后与 pET32a 可溶性核表达载体构建其重组核表达系统,并在大肠杆菌 BL21中表达,采用 Western 印迹及微量淋巴细胞毒阻断实验初步鉴定该蛋白的特异性及其生物学特性.结果:扩增出 HLA-B*2704重链胞外功能区 cDNA 片段,构建的HLA-B*2704 cDNA-pET32a 可溶性核表达载体可在大肠杆菌 BL21表达系统中得到较好表达,表达量约占菌体总蛋白的40%;通过 Western 印迹鉴定了表达蛋白的特异性;通过微量淋巴细胞毒阻断实验发现该重组蛋白具有生物活性并可特异性阻断 HLA-B27阳性细胞的微量淋巴细胞毒反应.结论:在大肠杆菌中表达了具有生物学活性的HLA-B*2704重链胞外功能区,为强直性脊柱炎的机理研究及特异性阻断药物的筛选提供了实验基础和新的靶标.     

无标签重组人硫氧还蛋白的大规模表达、纯化及活性检测

目的:利用基因工程的方法原核表达无标签的重组人硫氧还蛋白(rhTrx)并对其进行大规模表达、纯化和鉴定.方法:从人胚胎肾HEK293细胞中提取总RNA,反转录合成cDNA,经PCR扩增、酶切后连入pET-22b(+)载体构建重组质粒,重组质粒转化大肠杆菌BL21( DE3)感受态细胞,IPTG诱导表达,经两步离子交换层析纯化重组蛋白,采用SDS-PAGE、Western blotting、HPLC、MALDI-TOF-MS及经典的胰岛素二硫键还原法对重组蛋白进行鉴定.结果:构建成功了rhTrx基因表达载体;实现了rhTrx在原核细胞中的可溶性表达;纯化出的蛋白经SDS-PAGE和Western blotting分析证实为rhTrx;HPLC和MALDI-TOF-MS分析表明,纯化出的目的蛋白纯度大于95％;胰岛素二硫键还原法证实纯化出的rhTrx具有生物学活性.结论:成功构建了rhTrx的原核表达体系,建立了rhTrx的纯化和鉴定方法,为其进一步的理论研究和生产开发提供了有效基础数据.     

sTACI-Fc-Myc重组质粒的构建、原核表达及活性鉴定

目的:构建s TACI-Fc-Myc重组质粒,并进行原核表达和纯化具有生物活性的融合蛋白。方法:通过PCR法获得s TACI-Fc-Myc重组片段,然后把融合基因片段与原核载体p ET28a连接在一起,并构建p ET28a-s TACI-Fc-Myc重组子,并转入BL21(DE3)中进行表达,用蛋白A凝胶亲和层析柱进行纯化及酶联免疫吸附剂(ELISA)法测定其生物学活性。结果:获得了s TACI-Fc-Myc重组质粒,且该质粒可以在BL21(DE3)中表达,亲和层析柱纯化后纯度可达到95%以上,与BAFF的结合活性具有剂量依赖性,浓度达到5 ng/μL时,两者的吸附达到饱和。结论:成功构建了s TACI-Fc-Myc原核表达载体,并使有生物学活性的融合蛋白在BL21(DE3)上获得了稳定表达,为进一步研究并筛选高活性BAFF拮抗肽奠定了基础。     

重组牛肠激酶轻链基因在大肠杆菌中的表达与纯化

肠激酶（Enteroloinase,EK,EC3.4.21.9）是一种以异源二聚体形式存在于哺乳动物十二指肠内的丝氨酸蛋白酶,通过在位点（Asp）4-Lys的羧基端进行高效特异酶切,将胰蛋白酶原激活为胰蛋白酶。以GenBank公共数据库中牛肠激酶轻链基因序列（Accession No.NM174439）设计引物,利用RT-PCR方法合成牛肠激酶轻链基因片段,并克隆进pET39b载体中DsbA片段的C’端,转化大肠杆菌BL21（DE3）,获得DsbA/牛肠激酶轻链融合蛋白,经镍离子螯合层析纯化,每升培养液中可得到2.7-3.0mg重组牛肠激酶,对含有肠激酶酶切位点的IL-11/MBP融合蛋白进行酶切,结果表明,酶解率可达到95%以上,为重组牛肠激酶的大规模生产打下了基础。     

sBAFF mutants induce neutralizing antibodies against BAFF

B cell activating factor belonging to the TNF family (BAFF) is a novel member of the tumor necrosis factor (TNF) ligand family and plays an important role in B lymphocyte maturation and survival. Overexpression of BAFF is closely involved in the pathogenesis and progression of many kinds of autoimmune disorders; therefore, BAFF has been considered as an ideal therapeutic target for these conditions. In this study, we generated several candidate immune inhibitors of human BAFF by conjugating foreign immunodominant T-helper cell (Th) epitopes to the N- or C-terminus of five BAFF mutants. The recombined proteins were successfully expressed in Escherichia coli (E. coli) and purified by Ni-NTA chromatography. BALB/c mice immunized with the recombinant proteins produced high levels of anti-BAFF antibodies, and their sera inhibited the lymphocyte proliferation-inducing activity of recombinant soluble BAFF and natural soluble BAFF. Moreover, antibodies cross-reactive with BAFF were detected in sera from hu-SCID mice immunized with the recombinant proteins. These results indicated that the recombinant BAFF mutants modified with Th epitopes could induce neutralizing antibodies against BAFF in vivo. This study may provide a valuable strategy for treating BAFF-associated autoimmune diseases.     

热休克蛋白HSP65嵌合表达系统的构建和表达

设计一条含(GlySer)3连接肽的引物,从BCG经PCR得到HSP65-Linker的基因片段。将该基因定向克隆入原核表达载体pET42b(+),用大肠杆菌BL21(DE3)转化,构建了pET42-LHSP65的嵌合表达载体。DNA测序正确后经IPTG诱导表达,得到可溶性目的蛋白,Western-blot也证实了此重组蛋白可与抗HSP65发生特异性免疫反应。此重组体的构建为进一步探索HSP65的免疫佐剂功效奠定了基础。     

Oxidative Folding of Conopeptides Modified by <Emphasis Type="Italic">Conus</Emphasis> Protein Disulfide Isomerase

Protein disulfide isomerase is a type of enzyme that catalyses the oxidation, isomerization and reduction of disulfide bonds. Conotoxins that containing disulfide bonds are likely substrates of protein disulfide isomerise. Here, we cloned 12 protein disulfide isomerise genes from 12 different cone snail species that inhabited the sea near Sanya in China. The full-length amino acid sequences of these protein disulfide isomerase genes share a high degree of homology, including the same -CGHC- active site sequence and -RDEL- endoplasmic reticulum retention signal. To obtain enough conus protein disulfide isomerase for functional studies, we constructed the expression vector pET28a-sPDI. Conus protein disulfide isomerase was successfully expressed using Escherichia coli expression system and purified using chromatography method of affinity chromatography. The recombinant conus protein disulfide isomerase showed the ability to catalyse disulfide bond formation and rearrangement in the lysozyme enzyme activity assay. The role of conus protein disulfide isomerase in the in vitro oxidative folding of conotoxins was investigated using synthetic linear conotoxin lt14a, a peptide composed of 13 amino acids. It was confirmed by high performance liquid chromatography and mass spectrometry analysis that conus protein disulfide isomerase can catalyse the disulfide bond formation of linear lt14a. Then, conus protein disulfide isomerase was acted as a fusion partner during the production of engineered peptidyl-prolyl cis–trans isomerase and lt14a derived from cone snails. It was shown that peptidyl-prolyl cis–trans isomerase and conotoxin lt14a are successfully expressed in a highly soluble form by fusion with conus protein disulfide isomerase. Thus, conus protein disulfide isomerase functions not only as an enzyme that catalyses oxidative process but also a fusion partner in recombinant conotoxin expression.     

Expression of human cardiac-specific homeobox protein in Escherichia coli

Human cardiac-specific homeobox protein cDNA (hCsx) was cloned into expression plasmid pET32a and fused with Escherichia coli thioredoxin (Trx). The Trx-Csx fusion protein was under the control of bacteriophage T7 promoter. When expressed in E. coli BL21(DE3), about half of the recombinant Trx-Csx products existed in the form of insoluble inclusion bodies. When coexpressed with human protein disulfide isomerase, more than 90% of Trx-Csx products accumulated in the soluble form in the cell lysate. The recombinant Csx fusion protein was purified by one-step metal-chelating affinity chromatography.     

抗菌肽CM4与人可溶性B淋巴细胞因子hsBAFF在大肠杆菌中的融合表达

为进一步探讨抗菌肽CM4的原核表达及其生物学功能,本实验研究了抗菌肽CM4与人可溶性B淋巴细胞刺激因子hsBAFF的融合表达及抗菌肽CM4的生物学活性。运用PCR把B淋巴细胞因子hsBAFF和家蚕抗菌肽CM4进行基因融合,构建了融合表达载体pET28a (+)/CM4-hsBAFF,并在大肠杆菌中获得高可溶性表达的融合靶蛋白,且存在于超声破碎后的上清,经分子筛Sephadex G-75纯化后的重组融合蛋白用SDS-PAGE和Western blot分析鉴定.SDS-PAGE分析表明：可以通过分子筛一步纯化得到融合蛋白,该重组融合蛋白的分子量约22.0 KDa。Western blot结果显示该重组蛋白能与鼠抗人hsBAFF的抗体发生特异性反应.运用基因工程的方法获得CM4-hsBAFF重组融合蛋白,并具有很好的抑菌生物学活性。     

蛇毒纤溶酶Alfimeprase在大肠杆菌中的可溶表达和纯化

Alfimeprase是Fibrolase的突变体,是一种蛇毒纤溶酶,有纤溶活性而无出血性。根据Alfimeprase的氨基酸序列和大肠杆菌密码子偏爱性,利用PCR的方法合成Alfimeprase DNA序列,分别融合在NusA和MBP的C端,与分子伴侣FkpA在大肠杆菌Origami B(DE3)中共表达,融合蛋白NusA/Alfimeprase以部分可溶的形式存在,可溶部分占上清总蛋白的25%左右,通过镍柱亲合层析纯化和肠激酶切割得到具有纤溶活性的重组蛋白Alfimeprase。本研究是首次报道在大肠杆菌中可溶表达Alfimeprase,为以后深入研究其功能及应用奠定了基础。     

Soluble expression, purification, and stabilization of a pro-apoptotic human protein, CARP

CARP is a novel pro-apoptotic protein that has been cloned and characterized in our previous report. Previous studies showed that suppression of CARP expression results in cell proliferation in several mammalian cell lines and over-expression of CARP leads to apoptosis and inhibition of proliferation in seven tumor cell lines [Liu et al., CARP is a novel caspase recruitment domain containing pro-apoptotic protein, Biochem. Biophys. Res. Commun. 293 (2002) 1396]. To obtain soluble and active form of CARP protein for further functional and structural studies, we have expressed CARP in Escherichia coli by using Gateway cloning system. Optimal induction and expression conditions were also studied. Recombinant histidine-tagged CARP was expressed in E. coli when the carp gene was subcloned into a Gateway expression vector pET21-DEST. The partially soluble recombinant CARP protein was purified to near homogeneity by a two-step FPLC procedure, first by Ni2+ affinity chromatography followed by a gel-filtration chromatography, which yielded about 10 mg protein/L culture with at least 95% purity. Two peaks were detected in the analytical gel-filtration chromatograph while only one peak corresponding to monomer of the CARP protein was left after adding 2 mM dithiothreitol (DTT). The polymers observed are likely due to the formation of intermolecular disulfide bridges. These results suggest that adding DTT is a good solution to prevent the formation of disulfide bonds and to stabilize the protein. Successfully growing crystals of the purified CARP protein also proved that we can produce well folded CARP protein in E. coli.